1. First read about Jublia Antifungal Topical Solution and learn more about its indications and  contraindications and read and agree to the Waiver of Liability.
2. Next, accurately and truthfully complete and submit a medical consultation questionnaire
3. Your medial consultation will be reviewed by one of our Physicians and if approved you will receive a Jublia Topical Solution  prescription with 6  refills which can be filled at most any local United States pharmacy of your choice. No medication purchase required- you can choose any pharmacy where your medical insurance accepted.
4. This physician evaluation is RISK-FREE.  If  Jublia prescription is not appropriate for you there is No charge.  The initial consultation fee for the physician evaluation is only $49.95. 
5. If you choose EXPRESS service, your Jublia prescription will be called into your local United States pharmacy within approximately 24 hours.  If Jublia is not for you, the visit is FREE. 

Do NOT use Jublia if you are pregnant, attempting to become pregnant, or at a high risk of becoming pregnant. Jublia (efinaconazole)  is a Pregnancy JUBLIA is pregnancy category C, and should be used during pregnancy.
• Do NOT use Jublia if you are breast feeding.
• Do NOT use Jublia if you are allergic  or sensitive to any of the ingredients: efinaconazole in a solution base alcohol, butylated hydroxytoluene, C12-15 alkyl lactate, citric acid, cyclomethicone, diisopropyl adipate, disodium edetate, and purified water. 
• Jublia is contraindicated if you have diabetes, diabetic neuropathy
• Jublia is contraindicated if you have a history of immunosuppression or immune system disease, if you are HIV-positive, if you are on cancer chemotherapy treatment.
• Jublia is contraindicated if you are an organ transplant recipient
• Jublia is contraindicated if you are taking anti-seizure medication to control epilepsy
• Jublia is contraindicated if use topical corticosteroids on a repeated monthly basis or you use steroid inhalers regular basis.
• Jublia is contraindicated if you have severe case of nail fungus infection involving many nails and involving the entire nail to the cuticle with the nail crumbling and lifting from the nail bed accompanied by pain. You need to been seen by your physician or a podiatrist.
• Jublia is NOT approved for pediatric use, and we do NOT prescribe Jublia to anyone under the age of 18 
• Jublia is ONLY approved for use on toenails.  Do NOT use on fingernails. Do NOT use in eyes, orally, on mucous membranes or in vaginal area.

• Jublia Topical Solution is for EXTERNAL USE ONLY.  Avoid getting Jublia in your eyes, nose or mouth.  Flush with water and seek immediate medical attention! JUBLIA is for use on nails and surrounding skin only. Do not use JUBLIA in your mouth, eyes, or vagina. Use it exactly as instructed by your doctor.
• Apply Jublia Topical Solution only to toenails.  Do not apply intravaginally or to other areas of skin or to fingernails.
• Do NOT use nail polish, artificial nails, or any other cosmetic nail product on the nails with Jublia Topical Solution.
• Do NOT combine topical Jublia Topical Solution with any other systemic antifungal NAIL treatment.
• If the area of application shows signs of increased irritation such as increased redness, swelling, burning, blistering, or oozing, DISCONTINUE USE and seek immediate medical attention from your regular physician.
• Jublia is to be used as part of a comprehensive nail care program. 
• Jublia topical solution is flammable. Keep away from heat and flame. Avoid heat and flame while applying JUBLIA to your toenail.
• Keep away from children.
• If you get the medication in your eyes, rinse immediately with water and contact your regular physician or seek emergency medical treatment! 
• There are NO systemic effects when used appropriately

 
JUBLIA is a topically applied solution with negligible systemic absorption and no liver monitoring required
 
    No need for patient counseling for potential liver toxicity
    No need for liver function tests
    In vitro liver enzyme studies show that drug interactions are not expected

JUBLIA is an azole antifungal dosed once daily for 48 weeks for the treatment of onychomycosis of the toenail(s). Jublia is specifically formulated to reach the site of the onychomycosis, to treat toenail fungal infections. Jublia reaches the nail bed and the site of infections when applied as directed via broad coverage of multiple pathways. The formulation has low surface tension and low keratin binding affinity which may help JUBLIA reach the site of infection when applied as directed.
 
 
 
 

HOW TO APPLY JUBLIA with its flow-through brush applicator:

• : Your toenails should be clean and dry before you apply JUBLIA.
•  

Before you apply JUBLIA to your affected toenail, remove the cap from the JUBLIA bottle.
• 

Hold the bottle directly over the affected toenail and gently squeeze the bottle to apply one drop of JUBLIA onto the toenail.
•  

For the big toenail, also apply a second drop to the end of the toenail.
•  

Use the brush attached to the bottle to gently spread JUBLIA around the entire toenail including: the cuticle, folds of the skin next to the sides of the toenail, and underneath the nail. Do not squeeze the bottle while spreading JUBLIA with the brush.
 
• 5Repeat Steps 2 to 4 to apply JUBLIA to each affected toenail.
• 6 Let JUBLIA dry completely.
• 7 After applying JUBLIA to your affected toenails, place the cap on the bottle and screw it on tightly.
• 8Wash your hands with soap and water after applying JUBLIA.

Sticking With Treatment

JUBLIA should be applied once daily for 48 weeks, exactly as directed by your doctor. It may be useful for you to establish a routine or daily treatment time to help you stick to your treatment, such as:

    When you wake up in the morning
    After you shower*
    Just before bed

*Wait for at least 10 minutes after showering, bathing, or washing before applying JUBLIA.

• The  majority of patients using Jublia Topical Solution experience no side effects, any side effects are mild if any.  The side effects when used topically as directed are limited to:


Adverse events reported by >1% of subjects in Phase 3 studies:

    Ingrown toenail (2.3% vs 0.7% with vehicle)
    Application-site dermatitis (2.2% vs 0.2% with vehicle)
    Application-site vesicles (1.6% vs 0% with vehicle)
    Application-site pain (1.1% vs 0.2% with vehicle)